Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 121,522

Document Document Title
WO/2016/149765A1
The present disclosure relates generally to compounds having activity as voltage-gated sodium channel blockers and their use in the field of therapeutic treatment, including the therapy or management of conditions associated with excessi...  
WO/2016/152953A1
The objective of the present invention is to provide an analgesic drug that is a peripherally selective opioid κ-receptor agonist and reduces side effects based on opioid μ-receptor agonists such as drug dependency and respiratory depr...  
WO/2016/150481A1
The invention relates to the use of a composition from a plant extract of Withania somnifera, to treat or prevent amyloid-related diseases, including Alzheimer disease.  
WO/2016/152054A1
Provided are compositions by which problems of free-type ω3 fatty acids or ethyl ester-type ω3 fatty acids can be overcome. The present invention provides a medicinal composition and an edible composition for preventing and/or treating...  
WO/2016/153023A1
Provided is an amyloid fiber formation inhibitor comprising a compound represented by general formulas (I)-(III): (in the formulas, Q represents -C(=O)- or the like; X represents -C(=O)-, -NH-C(=O)-, or the like; Y represents -(CH2)m-, o...  
WO/2016/152519A1
Provided is an external medicine for diffuse plexiform neurofibroma. The external medicine for diffuse plexiform neurofibroma according to the present invention comprises as an active ingredient at least one member selected from the grou...  
WO/2016/151484A1
This invention relates to new inhibitors of butyrylcholinesterase with general formulas I and II, where substituents are described in patent description. Compounds can be in the form of pure enantiomers or as racemic mixtures, or in the ...  
WO/2016/154031A1
Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with ...  
WO/2016/151132A1
The invention relates to the use of biotin for treating Amyotrophic Lateral Sclerosis, as well as demyelinating peripheral neuropathies and Neuromyelitis optica (NMO).  
WO/2016/150785A1
The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pres...  
WO/2016/150971A1
The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7, to compositions conta...  
WO/2016/153957A3
Disclosed herein are methods and compositions for the intravenous administration of fumarates for the treatment of neurological diseases, such as stroke, amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, Parkinson...  
WO/2016/152952A1
The purpose of the present invention is to provide a compound having a potent analgesic effect on pain, particularly neuropathic pain. The present invention provides a cyclic amine derivative typified by chemical formula (1) or a pharmac...  
WO/2016/154522A1
This disclosure describes, in one aspect, immunogens effective for treating and/or diagnosing tauopathy, and immunotherapeutic compositions and methods involving those immunogens. Generally, the immunogen includes an antigen presentation...  
WO/2016/153948A1
The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the ...  
WO/2016/153065A1
A method for producing a DHA-containing glyceride-containing composition, said method including a step for obtaining a DHA-containing glyceride composition by conducting an esterification reaction by causing a lipase to act on starting m...  
WO/2016/152955A1
The purpose of the present invention is to provide a compound having a potent analgesic effect on pain, particularly neuropathic pain and/or fibromyalgia. The present invention provides a cyclic amine derivative typified by chemical form...  
WO/2016/153453A1
The present invention is related to a use of Adipokinetic hormone/Red pigment- concentrating hormone (AKH/RPCH) family of peptides. The current invention particularly relates to Adipokinetic hormone/Red pigment-concentrating hormone (AKH...  
WO/2016/150403A1
A method of treating and/or preventing neurological conditions, comprising administering to a subject in need thereof a therapeutically effective amount of a p75 extracellular domain (p75ECD) or a functional fragment, variant, analogue o...  
WO/2016/151483A1
This invention relates to new inhibitors of chymothrypsin-like activity of the immunoproteasome (inhibitors of β5ί or LMP7 subunit) with the general formula (I), where substituents are described in patent description. Compounds can be ...  
WO/2016/154434A1
In alternative embodiments, provided are selective agonists having a high affinity for the alpha7 nicotinic acetylcholine receptor (α7 nAChR), assays for selectivity of nicotinic receptor subtype and ligand-gated ion channel subtype bas...  
WO/2016/152846A1
The purpose of the present invention is to provide a composition for improving circadian rhythm that can be safely taken over a long time, in particular, a composition for controlling circadian rhythm that is capable of increasing circad...  
WO/2016/154329A3
The invention provides p38 MAPK inhibitors that compensate for a frataxin deficiency or mutation and methods of using the same (e.g., to treat Friedreichs ataxia).  
WO/2016/151328A1
The present invention relates to a process for preparing serotonin reuptake inhibitors of formula (I) and pharmaceutically acceptable salts thereof, (Formula (I)) wherein, R1, R2, R3, l, m, n and Z are as defined in the specification.  
WO/2016/148263A1
The problem addressed by the present invention is to provide a pharmaceutical solid preparation which comprises stabilized [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6 -yl]acetic acid monobenzene sulfonate, and to provide...  
WO/2016/149437A1
Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: -(CR3R3)2-5-, -(CR3R3)x-Y-(CR3R3)y-, -Y-(CR3R3)2-3-Y-, -CR3R3-Y-(CR3R3)2-Y-,-Y-(CR3R3)2-Y-CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein....  
WO/2016/146583A1
The present invention relates to a compound of the general formula (II) or a salt or solvate thereof, as well as medical uses involving them, wherein A1 is selected from the group consisting of N and C-R8; A2 is selected from the group c...  
WO/2016/147144A1
A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The 5 invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the us...  
WO/2016/149401A2
Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and composition...  
WO/2016/147185A1
Novel adenosine 5'-thiophosphate derivatives, represented by Formulae (I) or (I*), and salts thereof, represented by Formulae (Ia) and (I*a), as defined in the specification, and uses thereof as antioxidants and/or P2Y1-R agonists, and/o...  
WO/2016/148264A1
The problem addressed by the present invention is to provide a pharmaceutical solid preparation which comprises stabilized [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6 -yl]acetic acid monobenzene sulfonate, and to provide...  
WO/2016/148114A1
The invention of the present application can provide: a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which can achieve a definitive treatment, i.e., the inhibition of cell death, rather than conventio...  
WO/2016/149092A1
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injec...  
WO/2016/149439A1
Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CR6 or N; W is: (i) -(CR3R3)1-4- or (ii) -(CR3R3)x-Y-(CR3R3)y-; and Y, R1, R2, R3, R5, R6, R7, x, and y are define herein. Also disclosed are methods of using such c...  
WO/2016/148568A1
The invention pertains to the use of uridine and/or an equivalent thereof and n3-PUFA in the manufacture of a product for restoring or improving bladder function in a subject, in particular in a patient suffering from spinal cord injury.  
WO/2016/148260A1
Provided is a therapeutic and/or prophylactic agent or the like for early-stage Parkinson's disease which includes, as active ingredients, istradefylline (A), L-DOPA (B), and a dopamine agonist (C), and which is characterized in that the...  
WO/2016/149436A1
Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: (i) -(CR3R3)1-4-; (ii)-(CR3R3)x-Y-(CR3R3)y-; or (iii) -Y-(CR3R3)2-Y-; and Y, R1, R2, R3, R5, R6, R8, x, and y are defined herein. Also disclosed are methods...  
WO/2016/147108A1
The present invention relates to solid oral dosage forms of Dimethyl fumarate. More specifically, the present invention relates to delayed release compositions of Dimethyl fumarate and process for their preparation.  
WO/2016/147146A1
Citalopram or escitalopram, pharmaceutically acceptable salts or derivatives thereof for use in the treatment of neurodegenerative diseases The disclosure subject matter is related to the use of citalopram or escitalopram, pharmaceutical...  
WO/2016/147011A1
This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing ...  
WO/2016/145910A1
An application of nicotinamide adenine dinucleotide (NADH) and nicotinamide mononucleotide (NMN) in the preparation of a drug or health care product treating Parkinson's disease, β-NADH and β-NMN being prepared via enzyme catalysis.  
WO/2016/145628A1
A nutritional composition for enhancing cognitive development and learning skills comprises 3'-Siallylactose and 6'-Siallylactose in a weight ratio between 10:1 and 1:10.  
WO/2016/148232A1
The morphinan derivatives represented by general formula (I) (wherein R1 represents hydrogen, a C1-10alkyl, a cycloalkylalkyl in which the cycloalkyl moiety has 3-6 carbon atoms and the alkylene moiety has 1-5 carbon atoms, or the like; ...  
WO/2016/149169A1
Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein GAr, L1, Z1and Z2are as defined in the specification, are useful in treating conditions or disorders prevented by or ...  
WO/2016/148213A1
Disclosed are: any one polypeptide selected from (a) a polypeptide which comprises the amino acid sequence represented by SEQ ID NO: 1, (b) a polypeptide which comprises an amino acid sequence produced by deleting, substituting, insertin...  
WO/2016/148308A1
The present invention provides a therapeutic and/or prophylactic agent for, for example, frontal lobe dysfunction (for example, cognitive impairment (for example, cognitive impairment in Parkinson's disease, cognitive impairment caused b...  
WO/2016/149057A1
The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.  
WO/2016/148261A1
Provided is a therapeutic and/or prophylactic agent or the like for Lewy body diseases (such as Parkinson's disease dementia, diffuse Lewy body disease, Lewy body dementia, and Lewy body disease movement disorder) which includes istradef...  
WO/2016/145935A1
Provided is a series of new poly-fluorosubstituted pyrazolopyrimidine compounds or salts. The compounds are Bruton's tyrosine kinase (BTK) inhibitors. The compounds have better kinase inhibition selectivity and pharmokinetic properties. ...  
WO/2016/146600A1
The present invention relates to compounds of formula I wherein Y is C-R1; R1' is hydrogen, F or Cl; R1 is F or Cl; R2 is hydrogen or lower alkyl; R3 is phenyl, pyridinyl or isothiazolyl, wherein the N atom in the pyridinyl group may be ...  

Matches 701 - 750 out of 121,522